ResMed Inc. reported a strong financial performance for the second quarter of fiscal year 2026, with net revenue reaching $1.42 billion, an increase of 11% compared to $1.28 billion in the same period last year. The company's gross profit also saw a significant rise, climbing to $878.7 million, which translates to a gross margin of 61.8%, up from 58.6% in the prior year. Net income for the quarter was $392.6 million, or $2.68 per diluted share, reflecting a 14% increase in net income from $344.6 million, or $2.34 per diluted share, in the previous year.
In terms of operational metrics, ResMed's Sleep and Breathing Health segment generated $1.26 billion in revenue, marking a 12% increase year-over-year. This growth was driven by increased demand for devices and masks, with notable contributions from both the U.S. and international markets. The Residential Care Software segment also performed well, with revenues rising to $166.9 million, a 7% increase from the previous year. The company attributed its revenue growth to higher unit sales and improved market conditions.
ResMed's strategic initiatives included continued investment in research and development, with expenditures amounting to $91 million for the quarter, representing 6.4% of net revenues. The company launched its new AirSense 11 device, which features advanced technology aimed at enhancing patient care. Additionally, ResMed has been actively managing its operational costs, resulting in improved gross margins due to manufacturing efficiencies and cost reductions.
The company reported a total cash and cash equivalents balance of $1.42 billion as of December 31, 2025, an increase from $1.21 billion at the end of the previous fiscal year. ResMed's total assets reached $8.5 billion, while stockholders' equity stood at $6.32 billion. The company also noted a reduction in long-term debt, which decreased to $403.9 million from $658.4 million, reflecting its commitment to maintaining a strong balance sheet.
Looking ahead, ResMed expressed optimism about its growth trajectory, driven by ongoing product innovation and expansion into new markets. The company anticipates continued demand for its sleep and respiratory products, supported by a growing awareness of chronic respiratory conditions. ResMed's management remains focused on leveraging its technological advancements and operational efficiencies to enhance patient outcomes and drive shareholder value in the coming quarters.
About RESMED INC
ResMed Inc. specializes in digital health and cloud-connected medical devices for sleep and respiratory care. Its core offerings include CPAP, ventilators, diagnostic tools, and software solutions for sleep apnea, COPD, and other chronic respiratory diseases. Serving global markets, the company focuses on improving patient outcomes, enhancing therapy adherence, and streamlining care delivery through innovative products, connected care platforms, and residential care software.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.